- Home
- ANAB vs MEGI Comparison
ANAB vs MEGI Comparison
Compare ANAB & MEGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- MEGI
- Stock Information
- Founded
- ANAB 2005
- MEGI 2021
- Country
- ANAB United States
- MEGI United States
- Employees
- ANAB N/A
- MEGI N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- MEGI Investment Managers
- Sector
- ANAB Health Care
- MEGI Finance
- Exchange
- ANAB Nasdaq
- MEGI Nasdaq
- Market Cap
- ANAB 621.1M
- MEGI 729.7M
- IPO Year
- ANAB 2017
- MEGI N/A
- Fundamental
- Price
- ANAB $26.94
- MEGI $14.39
- Analyst Decision
- ANAB Buy
- MEGI
- Analyst Count
- ANAB 10
- MEGI 0
- Target Price
- ANAB $49.00
- MEGI N/A
- AVG Volume (30 Days)
- ANAB 526.3K
- MEGI 178.0K
- Earning Date
- ANAB 08-08-2025
- MEGI 01-01-0001
- Dividend Yield
- ANAB N/A
- MEGI 11.40%
- EPS Growth
- ANAB N/A
- MEGI N/A
- EPS
- ANAB N/A
- MEGI N/A
- Revenue
- ANAB $111,872,000.00
- MEGI N/A
- Revenue This Year
- ANAB N/A
- MEGI N/A
- Revenue Next Year
- ANAB $24.39
- MEGI N/A
- P/E Ratio
- ANAB N/A
- MEGI N/A
- Revenue Growth
- ANAB 387.20
- MEGI N/A
- 52 Week Low
- ANAB $12.21
- MEGI $10.63
- 52 Week High
- ANAB $41.31
- MEGI $14.89
- Technical
- Relative Strength Index (RSI)
- ANAB 66.30
- MEGI 55.61
- Support Level
- ANAB $25.48
- MEGI $14.00
- Resistance Level
- ANAB $28.50
- MEGI $14.53
- Average True Range (ATR)
- ANAB 1.26
- MEGI 0.20
- MACD
- ANAB 0.02
- MEGI 0.01
- Stochastic Oscillator
- ANAB 70.23
- MEGI 75.86
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund
NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.